Fabiana Letizia Cecere

机构：National Cancer Institute, Tumori Foundation, Istituti di Ricovero e Cura a Carattere Scientifico, Fondazione IRCCS Istituto Nazionale dei Tumori, Instituto Nazionale Tumori Regina Elena · ORCID：0000-0002-6881-6773

发表论文 136 篇 · 总被引 2042 次 · h-index 23

代表论文

• Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial (2023 · The Lancet · 被引 107)
• Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials (2023 · Critical Reviews in Oncology/Hematology · 被引 36)
• IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial. (2023 · Journal of Clinical Oncology · 被引 32)
• Urgent endovascular repair of juxtarenal/pararenal aneurysm by off-the-shelf multibranched endograft (2024 · Journal of Vascular Surgery · 被引 29)
• Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171) (2023 · Journal of Thoracic Oncology · 被引 22)
• A Real-World Systematic Analysis of Driver Mutations’ Prevalence in Early- and Advanced-Stage NSCLC: Implications for Targeted Therapies in the Adjuvant Setting (2022 · Cancers · 被引 20)